No it wasn't, the MC was overvalue then which was why my initial holding was very small. It was all dependent on the clinical trial from HER-Vaxx which they didn't released for over 12 months, now they have 3 clinical trials in parallel which has a much bigger market then Chemotherapy and long awaited clinical trial updates for 2 of them.
It's all about clinical trial when investing in biotech start-up stock and given the market hasn't value any of what IMU has achieved in the last 12 months, that's why it's a buy right now.
Ann: Imugene Confirms Pending Receipt of c.$11m R&D Tax Refund, page-49
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.001(7.69%) |
Mkt cap ! $104.5M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.4¢ | 1.2¢ | $267.3K | 20.57M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 788815 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.4¢ | 13241534 | 29 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |